Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)

por Sohn, Young Bae, Cho, Sung Yoon, Park, Sung Won, Kim, Su Jin, Ko, Ah-Ra, Kwon, Eun-Kyung, Han, Sun Ju, Jin, Dong-Kyu
Publicado 2013

Impact of Enzyme Replacement Therapy on Linear Growth in Korean Patients with Mucopolysaccharidosis Type II (Hunter Syndrome)

por Cho, Sung Yoon, Huh, Rimm, Chang, Mi Sun, Lee, Jieun, Kwun, Younghee, Maeng, Se Hyun, Kim, Su Jin, Sohn, Young Bae, Park, Sung Won, Kwon, Eun-Kyung, Han, Sun Ju, Jung, Jooyoun, Jin, Dong-Kyu
Publicado 2014

Clinical and molecular characterization of Korean children with infantile and late-onset Pompe disease: 10 years of experience with enzyme replacement therapy at a single center

por Kim, Min-Sun, Song, Ari, Im, Minji, Huh, June, Kang, I-Seok, Song, Jinyoung, Yang, Aram, Kim, Jinsup, Kwon, Eun-Kyung, Choi, Eu-Jin, Han, Sun-Ju, Park, Hyung-Doo, Cho, Sung Yoon, Jin, Dong-Kyu
Publicado 2019

A study of the relationship between clinical phenotypes and plasma iduronate-2-sulfatase enzyme activities in Hunter syndrome patients

por Lee, Ok Jeong, Kim, Su-Jin, Sohn, Young Bae, Park, Hyung-Doo, Lee, Soo-Youn, Kim, Chi-Hwa, Ko, Ah-Ra, Yook, Yeon-Joo, Lee, Su-Jin, Park, Sung Won, Kim, Se-Hwa, Cho, Sung-Yoon, Kwon, Eun-Kyung, Han, Sun Ju, Jin, Dong-Kyu
Publicado 2012